These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27622335)

  • 1. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
    Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
    Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
    Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
    Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer.
    Jia S; Jia Y; Liang S; Wu L
    Bioorg Med Chem; 2024 Aug; 110():117827. PubMed ID: 38964169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
    Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
    Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Pyrrolo[2,3-
    Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
    J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
    Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
    J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
    Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
    Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
    Clements ME; Holtslander L; Edwards C; Todd V; Dooyema SDR; Bullock K; Bergdorf K; Zahnow CA; Connolly RM; Johnson RW
    Oncogene; 2021 Aug; 40(34):5314-5326. PubMed ID: 34247191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
    Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
    Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
    Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
    Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
    Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
    Wei M; Xie M; Zhang Z; Wei Y; Zhang J; Pan H; Li B; Wang J; Song Y; Chong C; Zhao R; Wang J; Yu L; Yang G; Yang C
    Eur J Med Chem; 2020 Nov; 206():112677. PubMed ID: 32823005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.
    Vesci L; Bernasconi E; Milazzo FM; De Santis R; Gaudio E; Kwee I; Rinaldi A; Pace S; Carollo V; Giannini G; Bertoni F
    Oncotarget; 2015 Mar; 6(8):5735-48. PubMed ID: 25671299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.